A Comparison of Standard Vs Renal Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock.

Trial Profile

A Comparison of Standard Vs Renal Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Piperacillin/tazobactam (Primary)
  • Indications Bacterial infections; Septic shock
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Sep 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 01 Jul 2010 Planned end date changed from 1 Jun 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 01 Jul 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top